CA2332627A1 - Porcine circovirus and parvovirus vaccine - Google Patents

Porcine circovirus and parvovirus vaccine Download PDF

Info

Publication number
CA2332627A1
CA2332627A1 CA002332627A CA2332627A CA2332627A1 CA 2332627 A1 CA2332627 A1 CA 2332627A1 CA 002332627 A CA002332627 A CA 002332627A CA 2332627 A CA2332627 A CA 2332627A CA 2332627 A1 CA2332627 A1 CA 2332627A1
Authority
CA
Canada
Prior art keywords
antigen
porcine
circovirus
group
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002332627A
Other languages
French (fr)
Other versions
CA2332627C (en
Inventor
Gordon Moore Allan
Brian Martin Meehan
John Albert Ellis
George Steven Krakowka
Jean-Christophe Francis Audonnet
Francis Mcneilly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Boehringer Ingelheim Animal Health France SAS
Queens University of Belfast
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2332627A1 publication Critical patent/CA2332627A1/en
Application granted granted Critical
Publication of CA2332627C publication Critical patent/CA2332627C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/815—Viral vaccine for porcine species, e.g. swine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

The invention relates to antigenic preparations and vaccines directed agains t the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.

Claims (16)

1. Antigenic preparation directed against the PMWS
syndrome, comprising porcine circovirus antigen and porcine parvovirus antigen.
2. Preparation according to Claim 1, wherein it comprises type II porcine circovirus antigen.
3. Preparation according to claim 2, wherein the type II porcine circavirus antigen is an antigen of a circovirus selected from the group consisting of the preparations deposited at the ECACC, under the following references :
- accession. No. V97100219 - accession. No. V97100218 - accession. No. V97100217 - accession. No. V98011608 - accession. No. V98011609
4. Preparation according to any one of claims 1 to 3, wherein the porcine circovirus antigen and the porcine parvovirus antigen comprise, independently of each other, an antigen chosen from the group consisting of an attenuated live whole antigen, an inactivated whole antigen, a subunit antigen, a recombinant live vector and a DNA vector.
5. Preparation according to anyone of claims 1 to 4, wherein it comprises, in addition, an other valency which corresponds to another pig pathogen.
6. Preparation according to claim 5, wherein it comprises an other valency chosen among the group consisting of : PRRS, Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, E. coli, Atrophic Rhinitis, Pseudarabies, Hog cholera, Swine Influenza and combinations thereof.
7. Preparation according to claim 5, wherein it comprises an other valency which is PRRS.
8. Vaccine against the PMWS syndrome, comprising an effective quantity of an antigenic preparation according to any one of claims 1 to 7, in a vehicle or excipient acceptable from the veterinary point of view.
9. Vaccine according to claim 8, wherein it comprises an adjuvant acceptable from the veterinary point of view.
10. Vaccine according to claim 8 or 9, wherein it comprises antigens of several porcine circoviruses.
11. Vaccine according to any one claims 8 to 10, wherein it comprises circovirus antigen encoded by a circovirus open reading frame chosen among the group consisting of ORFs 1 to 13.
12. Vaccine according to claim 11, wherein it comprises circovirus antigen encoded by a circovirus open reading frame chosen among the group consisting of ORFs 4, 7, 10 and 13.
13. Vaccine according to any one of claims 8 to 12, wherein it comprises an expression vector selected from the group consisting of live viruses capable of multiplying in pigs without being pathogenic for pig, and DNA vectors, this expression vector comprising and expressing said ORF.
14. Vaccine according to claim 13, wherein the viral vector is a virus selected from the group consisting of pig herpes viruses, porcine adenovirus and poxviruses.
15. Vaccine according to claim 14, wherein the viral vector is a virus selected from the group consisting of Aujesky's disease virus, vaccinia virus, avipox virus, canarypox virus and swine pox virus.
16. Vaccination kit containing, packaged separately, a vaccine against the porcine circovirus according to any one of claims 8 to 15, and a vaccine against the porcine parvovirus.
CA2332627A 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine Expired - Lifetime CA2332627C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9808777A FR2781159B1 (en) 1998-07-06 1998-07-06 CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
FR98/08777 1998-07-06
PCT/EP1999/004698 WO2000001409A2 (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine

Publications (2)

Publication Number Publication Date
CA2332627A1 true CA2332627A1 (en) 2000-01-13
CA2332627C CA2332627C (en) 2010-06-01

Family

ID=9528441

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2332627A Expired - Lifetime CA2332627C (en) 1998-07-06 1999-06-28 Porcine circovirus and parvovirus vaccine

Country Status (22)

Country Link
US (2) US6217883B1 (en)
EP (1) EP1094837B1 (en)
JP (2) JP4749547B2 (en)
KR (1) KR100730336B1 (en)
CN (1) CN1168502C (en)
AT (1) ATE452653T1 (en)
AU (1) AU746234B2 (en)
BR (1) BRPI9911870B8 (en)
CA (1) CA2332627C (en)
CY (1) CY1110290T1 (en)
DE (1) DE69941843D1 (en)
DK (1) DK1094837T3 (en)
ES (1) ES2338616T3 (en)
FR (1) FR2781159B1 (en)
HU (1) HU227805B1 (en)
MX (1) MXPA00012785A (en)
PL (1) PL205299B1 (en)
PT (1) PT1094837E (en)
RU (1) RU2237492C2 (en)
TW (1) TWI221774B (en)
UA (1) UA72891C2 (en)
WO (1) WO2000001409A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7192594B2 (en) * 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
FR2781159B1 (en) * 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
FR2772047B1 (en) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E GENOMIC SEQUENCE AND POLYPEPTIDES OF CIRCOVIRUS ASSOCIATED WITH PIGLET LOSS DISEASE (MAP), APPLICATIONS TO DIAGNOSIS AND TO PREVENTION AND / OR TREATMENT OF INFECTION
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
KR100879650B1 (en) * 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 Postweaning multisystemic wasting syndrome virus from pigs
US6943152B1 (en) * 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
ES2170622B1 (en) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas CLONES AND INFECTIVE VECTORS DERIVED FROM CORONAVIRUS AND ITS APPLICATIONS.
DE10044648A1 (en) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Process for the propagation or removal of Cirocoviruses from biological material
PL202951B1 (en) * 2001-03-27 2009-08-31 Univ Saskatchewan Methods to culture circovirus
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
EP2390352A1 (en) 2003-03-18 2011-11-30 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20040258700A1 (en) * 2003-06-23 2004-12-23 Frimann Tine Holland Vaccine formulation with a preservative
WO2005049794A2 (en) 2003-11-13 2005-06-02 University Of Georgia Research Foundation, Inc. Methods of characterizing infectious bursal disease virus
CA2556911C (en) 2004-02-19 2013-07-30 The Governors Of The University Of Alberta Leptin promoter polymorphisms and uses thereof
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
SI2281829T1 (en) * 2004-12-30 2015-03-31 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions for use in a method of preventing PCV2 infection
UA95602C2 (en) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Pcv2 immunogenic compositions and methods of producing such compositions
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP1881845B1 (en) 2005-04-25 2010-03-24 Merial Ltd. Nipah virus vaccines
WO2006132598A1 (en) * 2005-06-07 2006-12-14 Temasek Life Sciences Laboratory Limited Porcine circovirus type 2 vaccines
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
KR100693077B1 (en) * 2005-11-03 2007-03-12 채찬희 Biological composition for preventing and treating prdc
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
CA2629522A1 (en) 2005-11-14 2007-05-18 Merial Limited Gene therapy for renal failure
DK3127551T3 (en) 2005-12-29 2020-10-12 Boehringer Ingelheim Animal Health Usa Inc PCV2 IMMUNOGENE COMPOSITION TO REDUCE CLINICAL SYMPTOMS IN PIGS
PL1968630T3 (en) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
WO2008127279A2 (en) * 2006-10-05 2008-10-23 Cerebus Biologicals, Inc. Methods for treating, preventing and diagnosing porcine ttv infection
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
BRPI0721083A2 (en) * 2006-12-15 2014-02-25 Boehringer Ingelheim Vetmed PCV2 ANTIGEN PIG TREATMENT
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101294224B (en) * 2007-05-08 2011-04-06 深圳太太基因工程有限公司 Primer and probe sequence for testing pig parvoviral nucleotide fragment
KR20100025529A (en) * 2007-05-30 2010-03-09 와이어쓰 엘엘씨 Raccoon poxvirus expressing genes of porcine virus
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
ME01156B (en) * 2007-12-21 2013-03-20 Zoetis Services Llc Methods and compositions for immunizing pigs against porcine circovirus
EP2231182A4 (en) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed Pcv2 orf2 virus like particle with foreign amino acid insertion
AU2009234345B2 (en) 2008-01-23 2013-08-22 Boehringer Ingelheim Vetmedica, Inc. PCV2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
US7927586B2 (en) * 2008-07-08 2011-04-19 South Dakota State University Vaccine for porcine post-weaning diarrhea caused by enterotoxigenic Escherichia coli
CA2757030C (en) 2009-04-03 2019-01-15 Merial Limited Vectors comprising newcastle disease viruses and compositions thereof
AR078253A1 (en) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed METHODS TO REDUCE ANTIVIRICAL ACTIVITY IN PCV-2 COMPOSITIONS AND PCV-2 COMPOSITIONS WITH BETTER IMMUNOGENICITY
CA2809127C (en) 2010-08-31 2019-04-02 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
CN101947318B (en) * 2010-09-09 2012-09-05 扬州优邦生物制药有限公司 Method for preparing porcine parvovirus inactivated vaccines
TWI442935B (en) 2010-12-22 2014-07-01 Sbc Virbac Ltd Porcine circovirus type 2, immunogenic composition containing the same, test kit, and application thereof
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
WO2012138783A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
WO2012138789A2 (en) 2011-04-04 2012-10-11 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2834288A1 (en) 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
WO2012166493A1 (en) 2011-06-01 2012-12-06 Merial Limited Needle-free administration of prrsv vaccines
JP6041361B2 (en) 2011-08-12 2016-12-07 メリアル インコーポレイテッド Vacuum storage of biological products, especially vaccines
UA113192C2 (en) * 2011-12-06 2016-12-26 IMMUNOGENIC COMPOSITION AGAINST PIG TYPE 2 (PCV2) CIRCULOSIS
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
CN105749273A (en) * 2012-01-13 2016-07-13 普莱柯生物工程股份有限公司 Bivalent inactivated vaccine for porcine circovirus type 2 and porcine parvovirus and preparation method thereof
CN102961742A (en) * 2012-01-13 2013-03-13 普莱柯生物工程股份有限公司 Bivalent inactivated vaccine of porcine circovirus type 2 and porcine parvovirus and preparation method thereof
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
CN102719407B (en) * 2012-05-25 2013-09-04 中国农业科学院哈尔滨兽医研究所 Porcine parvovirus BQ-C strain and application of porcine parvovirus BQ-C strain in preparation of inactivated porcine parvovirus vaccine
WO2014164697A1 (en) 2013-03-12 2014-10-09 Merial Limited Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof
DK2994162T3 (en) 2013-05-08 2021-06-21 Pharmgate Biologics Inc Vaccine for pcv2 og mycoplasma
EP3049106A1 (en) * 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
KR102409183B1 (en) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Pcv2 orf2 protein variant and virus like particles composed thereof
JP6605469B2 (en) 2013-12-03 2019-11-13 インターベット インターナショナル ベー． フェー． Vaccine against porcine circovirus type 2
CN104250640A (en) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 Porcine pseudorabies virus gene deletion strain, vaccine composition, preparation method and application thereof
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN105087506B (en) * 2015-03-20 2020-06-30 普莱柯生物工程股份有限公司 Porcine pseudorabies virus weakening method, porcine pseudorabies virus weakening virus strain, porcine pseudorabies virus vaccine composition and application of porcine pseudorabies virus weakening virus strain
US9944904B2 (en) 2015-05-14 2018-04-17 Merial Inc. Method for porcine circovirus production and PCV2 vaccines
AU2016282772B2 (en) 2015-06-23 2019-09-05 Boehringer Ingelheim Animal Health USA Inc. PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
CN108883169A (en) * 2016-03-23 2018-11-23 英特维特国际股份有限公司 For the intradermal application vaccine of PCV2 and PRRS virus infection
CN106435016B (en) * 2016-08-30 2019-07-26 中国农业科学院兰州兽医研究所 A kind of LAMP kit of quick colour-developing one-step method detection porcine circovirus 2 type
ES2942749T3 (en) 2016-11-03 2023-06-06 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus, and production methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1538305A1 (en) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Associated vaccine against peptospirosis and parvovirus infection of pigs
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
ES2026827A6 (en) 1991-03-26 1992-05-01 Ercros Sa Method for producing a subunit vaccine against porcine parvovirus.
FR2751224B1 (en) * 1996-07-19 1998-11-20 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST BREATHING AND PIG REPRODUCTIVE CONDITIONS
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (en) * 1998-07-06 2000-10-06 Merial Sas CIRCOVIRUS VACCINE AND PIG PARVOVIRUS
UA78180C2 (en) * 1997-10-03 2007-03-15 Меріаль Porcine circovirus, vaccines and diagnostic reagents

Also Published As

Publication number Publication date
US20020146431A1 (en) 2002-10-10
CA2332627C (en) 2010-06-01
CN1168502C (en) 2004-09-29
FR2781159A1 (en) 2000-01-21
RU2237492C2 (en) 2004-10-10
AU4907799A (en) 2000-01-24
PT1094837E (en) 2010-03-18
UA72891C2 (en) 2005-05-16
US6217883B1 (en) 2001-04-17
BR9911870A (en) 2001-03-27
TWI221774B (en) 2004-10-11
PL345948A1 (en) 2002-01-14
JP2003522106A (en) 2003-07-22
JP2010222359A (en) 2010-10-07
AU746234B2 (en) 2002-04-18
HU227805B1 (en) 2012-03-28
BR9911870B1 (en) 2014-08-12
BRPI9911870B8 (en) 2015-09-22
US6953581B2 (en) 2005-10-11
MXPA00012785A (en) 2002-04-24
HUP0102770A3 (en) 2004-10-28
DE69941843D1 (en) 2010-02-04
EP1094837B1 (en) 2009-12-23
KR100730336B1 (en) 2007-06-19
JP4749547B2 (en) 2011-08-17
ATE452653T1 (en) 2010-01-15
PL205299B1 (en) 2010-04-30
WO2000001409A2 (en) 2000-01-13
DK1094837T3 (en) 2010-04-12
ES2338616T3 (en) 2010-05-10
HUP0102770A2 (en) 2001-11-28
CY1110290T1 (en) 2015-01-14
WO2000001409A3 (en) 2000-06-29
FR2781159B1 (en) 2000-10-06
EP1094837A2 (en) 2001-05-02
KR20010081991A (en) 2001-08-29
CN1311690A (en) 2001-09-05

Similar Documents

Publication Publication Date Title
CA2332627A1 (en) Porcine circovirus and parvovirus vaccine
RU2001103135A (en) VACCINE AGAINST CIRCOVIRUS AND PIG PARVOVIRUS
JP7445375B2 (en) Porcine circovirus type 3 immunogenic composition, method for producing the same, and method for using the same
CA2451626A1 (en) One dose vaccination with mycoplasma hyopneumoniae
ES2778425T3 (en) PCV2 ORF2 protein variant and virus-like particles composed of it
JP5200223B2 (en) Treatment of pigs with PCV2 antigen
CN1329513C (en) Avian polynucleotide vaccine formula for anti pig's diseases
AU2009236669B2 (en) Chimeric porcine circovirus PCV2Gen-1Rep and uses thereof
Gagnon et al. Adenoviral-expressed GP 5 of porcine respiratory and reproductive syndrome virus differs in its cellular maturation from the authentic viral protein but maintains known biological functions
US20100150959A1 (en) PCV 2-Based Methods and Compositions for the Treatment of Pigs
HRP20140002A2 (en) Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof
MXPA02011545A (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine.
RU2000111496A (en) NEW PIGS CIRCUS VIRUSES, VACCINES AND REAGENTS FOR DIAGNOSTICS
RU2727899C2 (en) Recombinant swine pox (swinepox) virus and vaccines
US20180236056A1 (en) Needle-free administration of PRRSV vaccines
US20210338792A1 (en) Vaccination against porcine circoviruses
AU2010307250B2 (en) Infectious clones of Torque teno virus
CA2439872A1 (en) Leporipox-based vector vaccines
RU2798442C2 (en) Vaccination against porcine circoviruses
US20220249650A1 (en) Senecavirus a virus strains and immunogenic compositions therefrom
US20200390878A1 (en) Recombinant swinepox virus and vaccines
Jiang et al. Construction and immunogenicity of recombinant pseudorabies virus expressing the modified GP5m protein of porcine reproduction and respiratory syndrome virus
JP2019509302A (en) Combination vaccine against PCV2 and PRRS virus infections containing albumin
RU99103293A (en) FORMULA OF POLYNUCLEOTIDE VACCINE AGAINST RESPIRATORY PATHOLOGIES AND PATIENTS OF PIG REPRODUCTION
RU99103298A (en) FORMULA OF POLYNUCLEOTID VACCINE AGAINST DOG PATHOLOGIES, IN PARTICULAR, RESPIRATORY PATHOLOGIES AND DIGESTION PATHOLOGIES

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190628